Comment on "Heterologous adenovirus-vector/messenger RNA regimen, humoral response and liver transplant recipients"

doi:10.1002/hep4.2071

. 2022 Dec;6(12):3598.

doi: 10.1002/hep4.2071. Epub 2022 Aug 23.

Comment on "Heterologous adenovirus-vector/messenger RNA regimen, humoral response and liver transplant recipients"

Pathum Sookaromdee¹, Viroj Wiwanitkit²

Affiliations

PMID: 35998273
DOI: 10.1002/hep4.2071

Free article

Comment on "Heterologous adenovirus-vector/messenger RNA regimen, humoral response and liver transplant recipients"

Pathum Sookaromdee et al. Hepatol Commun. 2022 Dec.

Free article

. 2022 Dec;6(12):3598.

doi: 10.1002/hep4.2071. Epub 2022 Aug 23.

Authors

Pathum Sookaromdee¹, Viroj Wiwanitkit²

Affiliations

¹ Private Academic Consultant, Bangkok, Thailand.
² Honorary Professor, Dr. D. Y. Patil University, Pune, India.

PMID: 35998273
DOI: 10.1002/hep4.2071

No abstract available

Similar articles

Heterologous adenovirus-vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients.
Mendizabal M, Ducasa N, Benencio P, Anders M, Cairo F, Barbero M, Etcheves P, Alter A, Scarton G, Abraldes JG, Biglione M, Mauro E. Mendizabal M, et al. Hepatol Commun. 2022 Oct;6(10):2850-2859. doi: 10.1002/hep4.2034. Epub 2022 Jul 28. Hepatol Commun. 2022. PMID: 35903818 Free PMC article.
Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients.
Schmidt T, Klemis V, Schub D, Schneitler S, Reichert MC, Wilkens H, Sester U, Sester M, Mihm J. Schmidt T, et al. Am J Transplant. 2021 Dec;21(12):3990-4002. doi: 10.1111/ajt.16818. Epub 2021 Sep 6. Am J Transplant. 2021. PMID: 34453872 Free PMC article.
Coordinated cellular and humoral immune responses after two-dose SARS-CoV2 mRNA vaccination in liver transplant recipients.
D'Offizi G, Agrati C, Visco-Comandini U, Castilletti C, Puro V, Piccolo P, Montalbano M, Meschi S, Tartaglia E, Sorace C, Leone S, Lapa D, Grassi G, Goletti D, Ippolito G, Vaia F, Ettorre GM, Lionetti R. D'Offizi G, et al. Liver Int. 2022 Jan;42(1):180-186. doi: 10.1111/liv.15089. Epub 2021 Nov 17. Liver Int. 2022. PMID: 34719107 Free PMC article.
Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
Tanner R, Starr N, Chan G, Dempsey E, Heffernan E, Newman E, O'Neill J, Hannan MM, Lynch B, Joyce E. Tanner R, et al. J Heart Lung Transplant. 2022 Apr;41(4):492-500. doi: 10.1016/j.healun.2022.01.005. Epub 2022 Jan 10. J Heart Lung Transplant. 2022. PMID: 35090809 Free PMC article.
Humoral response to heterologous prime-booster vaccination in heart transplant recipients aged 18-70 years primed with a viral vector SARS-CoV-2 vaccine.
Tanner R, Starr N, Perez-Garcia CN, Chan G, Dempsey E, Heffernan E, Lynch B, Hannan MM, Joyce E. Tanner R, et al. Transpl Infect Dis. 2022 Aug 18:e13935. doi: 10.1111/tid.13935. Online ahead of print. Transpl Infect Dis. 2022. PMID: 35980217 Free PMC article.

See all similar articles

References

REFERENCES

1. Mendizabal M, Ducasa N, Benencio P, Anders M, Cairo F, Barbero M, et al. Heterologous adenovirus-vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients. Hepatol Commun. 2022 Jul 28. https://doi.org/10.1002/hep4.2034. [Epub ahead of print]
1. Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health. 2020;53:70.
1. Gobbi F, Buonfrate D, Moro L, Rodari P, Piubelli C, Caldrer S, et al. Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection. Viruses. 2021;13:422.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Wiley
Medical
- MedlinePlus Health Information

[1] Mendizabal M, Ducasa N, Benencio P, Anders M, Cairo F, Barbero M, et al. Heterologous adenovirus-vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients. Hepatol Commun. 2022 Jul 28. https://doi.org/10.1002/hep4.2034. [Epub ahead of print]

[2] Mendizabal M, Ducasa N, Benencio P, Anders M, Cairo F, Barbero M, et al. Heterologous adenovirus-vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients. Hepatol Commun. 2022 Jul 28. https://doi.org/10.1002/hep4.2034. [Epub ahead of print]

[3] Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health. 2020;53:70.

[4] Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health. 2020;53:70.

[5] Gobbi F, Buonfrate D, Moro L, Rodari P, Piubelli C, Caldrer S, et al. Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection. Viruses. 2021;13:422.

[6] Gobbi F, Buonfrate D, Moro L, Rodari P, Piubelli C, Caldrer S, et al. Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection. Viruses. 2021;13:422.

Similar articles

References

REFERENCES

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical